- 2025 ESG Report
-
Samsung Biologics has published its 2025 ESG Report, which outlines the company's ESG initiatives, strategies, and plans for 2024–2025. This report was prepared to transparently disclose to stakeholders our activities to improve ESG-related issues and the impact of our business on the external society and environment. Samsung Biologics will continue to engage with stakeholders through the annual publication of ESG reports and aspires to become a company that grows in tandem with them.
- Reporting Period
-
This report covers the company's economic, social, and environmental performance and activities from January 1 to December 31, 2024, and for some key results, up to the time of publication in 2025. To help understand annual trends, we have included three-year data from 2022 to 2024 for quantitative performance.
- Reporting Standards
-
This report aligns with the Global Reporting Initiative (GRI) Standards 2021, which are the standards for sustainability reporting. ISO 26000, the UN Global Compact Principles, the IR Framework, the Sustainability Accounting Standards Board (SASB) information disclosure standards, the European Sustainability Reporting Standards (ESRS), International Sustainability Standards Board (ISSB), and Task Force on Climate-related Financial Disclosure (TCFD) recommendations were referenced when writing the report.
- Reporting Scope
-
This report covers the ESG management activities and performance of all business sites in and outside of South Korea. Financial data is provided in the K-IFRS consolidated format, and non-financial data includes Samsung Biologics’ business sites in Korea and data from Samsung Bioepis, a subsidiary of the company. This report is for the fiscal year in line with the disclosure system of the company, and the energy consumption data and greenhouse gas emissions provided are based on the verification result.
2025 ESG Report
Samsung Biologics has published its 2025 ESG Report, which outlines the company's ESG initiatives, strategies, and plans for 2024–2025. This report was prepared to transparently disclose to stakeholders our activities to improve ESG-related issues and the impact of our business on the external society and environment. Samsung Biologics will continue to engage with stakeholders through the annual publication of ESG reports and aspires to become a company that grows in tandem with them.
- Reporting Period
-
This report covers the company's economic, social, and environmental performance and activities from January 1 to December 31, 2024, and for some key results, up to the time of publication in 2025. To help understand annual trends, we have included three-year data from 2022 to 2024 for quantitative performance.
- Reporting Standards
-
This report aligns with the Global Reporting Initiative (GRI) Standards 2021, which are the standards for sustainability reporting. ISO 26000, the UN Global Compact Principles, the IR Framework, the Sustainability Accounting Standards Board (SASB) information disclosure standards, the European Sustainability Reporting Standards (ESRS), International Sustainability Standards Board (ISSB), and Task Force on Climate-related Financial Disclosure (TCFD) recommendations were referenced when writing the report.
- Reporting Scope
-
This report covers the ESG management activities and performance of all business sites in and outside of South Korea. Financial data is provided in the K-IFRS consolidated format, and non-financial data includes Samsung Biologics’ business sites in Korea and data from Samsung Bioepis, a subsidiary of the company. This report is for the fiscal year in line with the disclosure system of the company, and the energy consumption data and greenhouse gas emissions provided are based on the verification result.